Qsemble Capital Management LP Trims Stock Position in Eli Lilly and Company $LLY

Key Points

• Qsemble Capital Management cut its Eli Lilly position by 74.3% in the second quarter, selling 7,090 shares and retaining 2,448 shares valued at approximately $2.94 million. Hedge funds and other institutional investors collectively own 82.53% of LLY.
• Eli Lilly reported strong quarterly results, with revenue up 47.7% year over year to $22.97 billion and EPS of $8.38, beating expectations. The company also raised or set fiscal 2026 guidance at $35.50–$36.50 EPS, supported by growth in Mounjaro, Zepbound and its obesity-drug pipeline.
• Analysts maintain a broadly positive view, with a consensus “Moderate Buy” rating and a $1,292.18 target price, but recent insider selling and LLY’s elevated valuation could create near-term pressure.

Qsemble Capital Management LP cut its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 74.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,448 shares of the company's stock after selling 7,090 shares during the period. Qsemble Capital Management LP's holdings in Eli Lilly and Company were worth $2,936,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $25,000. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $30,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after buying an additional 24 shares during the last quarter. New England Capital Financial Advisors LLC grew its holdings in Eli Lilly and Company by 142.9% during the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company's stock worth $37,000 after acquiring an additional 20 shares during the period. Finally, Maseco LLP raised its position in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after acquiring an additional 28 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. regulator approved Lilly’s once-daily oral weight-loss pill, Foundayo (orforglipron), giving the company a potentially important first-mover advantage for an obesity pill in Europe. The approval expands Lilly’s addressable market beyond injectable treatments such as Mounjaro and Zepbound. Eli Lilly Just Scored Europe's First Weight Loss Pill Approval
• Positive Sentiment: Lilly is expanding its obesity pipeline with a new Phase 1 macupatide study in Japan. Although early-stage, the trial reinforces the company’s efforts to develop additional weight-management therapies and support long-term growth. Lilly Expands Obesity Pipeline With Fresh Macupatide Trial in Japan
• Positive Sentiment: Recent earnings showed continued operating momentum: quarterly revenue rose about 48% year over year to roughly $23 billion, while adjusted EPS beat expectations. Growth was led by Mounjaro, Zepbound and other key medicines, and management raised full-year 2026 guidance. Foundayo also generated an initial $98 million in quarterly sales. 5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call
• Neutral Sentiment: Analysts continue to view LLY as a fundamental leader, with reported price targets generally above the current trading level. However, the stock is approaching a technical buy point after a large earnings-driven advance, making valuation and chart resistance important near-term considerations. Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains
• Negative Sentiment: Insider-selling headlines may be adding pressure: executives have sold shares in recent months, including a reported 2,000-share sale by CFO and Chief Accounting Officer Donald Zakrowski. Lilly also trades at a demanding earnings multiple, leaving the stock sensitive to profit-taking or any signs of slower obesity-drug growth. Donald Zakrowski Sells 2,000 Shares of Eli Lilly Stock

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company's stock, valued at $14,131,250. This represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on LLY. Weiss Ratings lowered Eli Lilly and Company from a "buy (b)" rating to a "buy (b-)" rating in a research report on Tuesday, August 11th. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Citigroup boosted their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Bank of America increased their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a report on Friday, July 10th. Finally, Berenberg Bank raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a "hold" rating in a research report on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus target price of $1,292.18.

Eli Lilly and Company Stock Up 0.2%

Shares of LLY opened at $1,182.24 on Monday. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 12 month low of $685.15 and a 12 month high of $1,249.45. The stock's 50 day moving average is $1,170.82 and its two-hundred day moving average is $1,052.69. The firm has a market cap of $1.11 trillion, a P/E ratio of 39.67, a PEG ratio of 1.39 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business's revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts predict that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's payout ratio is presently 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source